NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
BörsenkürzelNURO
Name des UnternehmensNeuroMetrix Inc
IPO-datumJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeJul 22
Addresse1000 Winter Street
StadtWALTHAM
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02451
Telefon17818909989
Websitehttps://www.neurometrix.com/
BörsenkürzelNURO
IPO-datumJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten